Objectives: Stereotactic body radiation therapy (SBRT) takes advantage of the prostate's low
α/β ratio to deliver a large radiation dose in few fractions. Initial studies on small groups of …

Abstract Background Stereotactic Body Radiotherapy (SBRT) has excellent control rates for
low-and intermediate-risk prostate carcinoma. The role of SBRT for high-risk disease …

Objective The low alpha/beta ratio of prostate cancer suggests that hypofractionated
schemes of dose-escalated radiotherapy should be advantageous. We report our …

Purpose Hypofractionated, stereotactic body radiotherapy (SBRT) is an emerging treatment
approach for prostate cancer. We present the outcomes for low-risk prostate cancer patients …

Background We report the outcome of a phase I/II clinical trial of stereotactic body radiation
therapy (SBRT) for low (LR) and select intermediate risk (IR) prostate cancer (PCa) patients …

Purpose The radiobiology of prostate cancer may favor the extreme hypofractionation
inherent in stereotactic body radiation therapy (SBRT); however, data from a large …

Purpose Utilization of stereotactic body radiation therapy (SBRT) for treatment of localized
prostate cancer is increasing. Guidelines and payers variably support the use of prostate …

Background Stereotactic body radiation therapy (SBRT) delivers fewer high-dose fractions of
radiation which may be radiobiologically favorable to conventional low-dose fractions …

Background Stereotactic body radiotherapy (SBRT) may yield disease control for prostate
cancer in a brief, hypofractionated treatment regimen without increasing treatment toxicity …

With over a decade׳ s worth of clinical experience to guide stereotactic body radiotherapy
(SBRT) for the treatment of clinically localized prostate cancer (PCa), sufficient data exist for …